The two Spanish companies ended their 2022 with good figures, surpassing those achieved in 2021. The CEO of Cantabria Labs announced through a press release that the revenue closed at 293 million euros what means 21% of growth with regard to the previous year.
In the same document, they highlight, that like laboratory have positioned like leaders in dermatological prescription in Spain, Italy and Portugal. Besides, Cantabria Labs is the numer 1 in the market of immunostimulants in Spain and number1 in the digital field in the ranking of the pharmaceutical companies with better reputation. Regarding launches, the company highlights its innovative drug that has been the first topical finasteride registered in Europe, known in Spain, Italy, and Portugal as Alocare solution.
Cantabria Labs takes on 2023 with the challenge of consolidating its presence in the French market with the integration of ACM Laboratoire Dermatologique as Cantabria Labs France and the absorption of Deutera, an innovative Italian company that researches and manufactures products in the field of clinical nutrition.
mesoestic presents the best in results
The pharmaceutical laboratory skilled Catalan in cosmetic and aesthetic medicine summoned the media to a meeting in which they exposed the last economic results of the exercise of 2022, the best exercise of his history.
mesoestetic grew by 35% this 2022 compared to the previous year, reaching a turnover of 6.9 million euros compared to the 5.8 million recorded in 2021. This represents a 15% increase in business volume for the company based in Catalonia, compared to last year. In its detailed turnover, it can be seen that the strong point of Mesoestetic Pharma Group continues to be its home care products, which account for 40-50% of its turnover, followed by aesthetic medicine and cabin products, which both represent around 20-25%. In terms of net profit, Mesoestetic Pharma Group has accumulated 14.5 million euros.
At the results presentation event, Carles Font, Director of Business Development and Foreign Trade, Joan Carles Font, President and Founder of the company, David Caña, Director of Control and Organizational Management and Development, and Xavier Font, Director of Legal and Compliance Area were present.
As it explained the President and Founder of of mesoestetic® Pharma Group: "The business model of mesoestetic® is robust enough to ensure that success continues to accompany us. For this, we have three fundamental pillars: firstly, economic management, in order to have good financial health to face the challenges; secondly, a team of people working to make this project grow every day; and thirdly, constant investment and reinvestment. "
2022 was a very important year for mesoestotetic in terms of innovation and this was also reflected in the budget items of its financial year. "Investment in R&D&i in 2022 was 44% of annual profits. We have invested in PPE and solutions. In terms of sustainability, we have invested in our photovoltaic plant which, with its panels, manages to generate the energy consumed during the day and allows a 60% saving compared to what we used to consume," explained David Cañas, Director of Control and Organizational Management and Development. He also took the opportunity to comment that the R&D laboratories had been expanded by up to 600 m2. Other investments made have been in digitization, to which they have allocated an additional €200,000.
The despigmentant line has positioned like a 'top world-wide', although Carles Font, wanted to clear up that this depends a lot of the types of markets: "the mesoterapics products with certificate CE are a world-wide reference, but the domiciliary products also work very well."
Carles Font explained to the assistants that mesoestetic® positions like generators of scientific knowledge with 3 exclusive patents in the last years, being present in 15 national congresses and international and 33 institutions collaborators and verify year after year his commitment RDX
The internationalisation in the focus
The internationalisation is an essential pillar and an area to explode for mesoestetic® knowing new markets through the installation of new headquarters. In the last quarter, as they explained during the act, pretend to open a headquarters in Dubai. They expect, that on a long-term basis, his commercial relation with China, country in which they already enjoy of an acceptance by part of this market, derive in the construction of a subsidiary with staff, that allow them explore new territories like Thailand, Vietnam or Philippines. The past 2022 resolved with a presence in 109 countries of the products of the Catalan laboratory, and the subsidiary of Poland, that opened in 2020, has turned into 3% of the volume of business of mesoestetic® and opens the possibility to open two subsidiaries more in the European continent.